Market Research Industry Reports

Lonza Group Ltd (LONN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Lonza Group Ltd (Lonza) is a biopharmaceutical company that manufactures and develops chemical and biological active pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem cell therapies, drinking water sanitizers, vitamin B compounds, industrial preservatives, microbial control solutions and organic personal care ingredients. It also provides custom development and custom manufacturing services to its clients. Lonzas client base includes professionals in the biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; distributors; formulators and service companies. The companys key markets include bioresearch, nutrition, pharma and biotech, microbial control, agriculture, materials science and personal care industries. It operates several manufacturing and research and development (R&D) facilities across Asia, Europe and Americas. Lonza is headquartered in Basel, Switzerland.

Lonza Group Ltd (LONN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 6
List of Figures 7
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Lonza Group Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Lonza to Acquire Mammalian Manufacturing Site from Shire 16
Capsugel Acquires Ionic Liquids Technology from Monash University 17
InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 18
Venture Financing 19
Odyssey Thera Raises US$3 Million In Venture Financing 19
Private Equity 20
Kainos Capital Acquires InterHealth Nutraceuticals 20
Partnerships 21
BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 21
Synpromics Enters into Partnership with Lonza 22
Lonza Enters into Agreement with Denali Therapeutics 23
Capsugel Enters into Agreement with Pulmatrix 24
Lonza Enters into Agreement with Kodiak Sciences 25
CiMaas Enters into Agreement with PharmaCell 26
Lonza Partners with Octane Biotech 27
Capsugel Enter into Co-Development Agreement with Cardax for Astaxanthin Products 28
Lonza and AMYRA Biotech Enter into Agreement 29
Quotient Clinical Enters Into Co-Development Agreement With Capsugel 30
Catalent Pharma Solutions Enters Into Agreement With Bend Research 31
CSIRO Enters Into Co-Development Agreement With Lonza 32
Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 33
Licensing Agreements 34
Tillotts Pharma Enters into Licensing Agreement with BioWa and Lonza 34
CytoDyn Enters into Licensing Agreement with Lonza Sales 35
Xbiotech Enters into Licensing Agreement with Lonza Sales 36
Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 37
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 39
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 40
Pierre Fabre Enters into Licensing Agreement with Lonza 41
Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 42
Pierre Fabre Enters into Licensing Agreement with Lonza 43
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 44
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 45
Lonza Enters into Licensing Agreement with arGEN-X 47
Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 48
Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 49
Bend Research Enters Into Licensing Agreement With Affinium For SDD Technology 50
Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 51
Equity Offering 52
Lonza Raise USD2.24 Billion in Rights Offering of Shares 52
Lonza Raises USD871 Million in Private Placement of Shares 53
Debt Offering 54
Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 54
Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For US$316.5 Million 55
Lonza Completes Public Offering Of Bonds Due 2022 For US$112 Million 56
Lonza Completes Public Offering Of Bonds Due 2018 For US$213 Million 57
Asset Transactions 58
PolyPeptide to Acquire Peptides Business and Operations in Braine, Belgium from Lonza 58
Acquisition 59
Lonza Group Acquires micromacinazione from Cross 59
Lonza Acquires Capsugel from KKR & Co for USD5.5 Billion 60
Lonza Group Acquires PharmaCell 62
Lonza Acquires HansaBioMed Life Sciences 63
Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 64
Lonza Acquires Triangle Research Labs from PBM Capital 65
Lonza May Acquire Catalent 66
Capsugel Acquires Xcelience 67
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 68
PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 69
Capsugel Completes Acquisition Of Bend Research, Drug Delivery Technologies Company 70
Capsugel Belgium Acquires Encap Drug Delivery 71
Lonza Group Ltd - Key Competitors 72
Lonza Group Ltd - Key Employees 73
Lonza Group Ltd - Locations And Subsidiaries 74
Head Office 74
Other Locations & Subsidiaries 74
Joint Venture 77
Recent Developments 78
Strategy And Business Planning 78
Feb 27, 2018: Lonza Group Inaugurates New Research and Development Center for South America in Salto, Brazil 78
Feb 14, 2018: Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate Growth 79
Aug 24, 2017: Lonza to Increase and Expand Capabilities for Drug Product Services for Parenteral Dosage Forms 80
Financial Announcements 81
Jan 31, 2018: Lonza Reports Record-Breaking Full-Year Results with Double-Digit Lonza Standalone Sales Growth and More than 26% CORE EBIT Growth in a Major Transformational Year 81
Oct 26, 2017: Lonza Reports a Strong Third Quarter and Capsugel Integration on Track 85
Jul 26, 2017: Lonza Delivers Strong Performance in First Half 2017 and Sets a Strong Foundation for Continued Attractive Mid-Term Growth 87
Jan 25, 2017: Lonza Reports Record-Breaking Financial Performance, Resulting in 24.2% CORE EBIT Growth, Driven by Pharma and Biotech 89
Corporate Communications 91
Jun 27, 2017: Lonzas CHRO Elected to Board of Advance Women in Swiss Business 91
Jan 25, 2017: Lonza Appoints Fridtjof Helemann, CHRO, to Executive Committee 92
Product News 93
Nov 08, 2017: Lonza Launches XS Pichia 2.0 Expression and Manufacturing Platform for Development of Next Generation Therapeutics 93
Feb 15, 2018: Study Further Positions Lonzas UC-II A Undenatured Type II Collagen as a Leader in the Crowded Joint-Health Market 94
Other Significant Developments 95
Mar 26, 2018: Lonza to Host New Webinar: Integrating Devices into Quality Systems 95
Feb 20, 2018: Lonza Expands Encapsulation and HPAPI Capabilities in North America 96
Dec 14, 2017: Serialization Capabilities Now Operational at Lonza Edinburgh Facility for Liquid-Filled Hard Capsules 97
Appendix 99
Methodology 99
About GlobalData 99
Contact Us 99
Disclaimer 99

List Of Tables

List of Tables
Lonza Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Lonza Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Lonza Group Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Lonza to Acquire Mammalian Manufacturing Site from Shire 16
Capsugel Acquires Ionic Liquids Technology from Monash University 17
InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 18
Odyssey Thera Raises US$3 Million In Venture Financing 19
Kainos Capital Acquires InterHealth Nutraceuticals 20
BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 21
Synpromics Enters into Partnership with Lonza 22
Lonza Enters into Agreement with Denali Therapeutics 23
Capsugel Enters into Agreement with Pulmatrix 24
Lonza Enters into Agreement with Kodiak Sciences 25
CiMaas Enters into Agreement with PharmaCell 26
Lonza Partners with Octane Biotech 27
Capsugel Enter into Co-Development Agreement with Cardax for Astaxanthin Products 28
Lonza and AMYRA Biotech Enter into Agreement 29
Quotient Clinical Enters Into Co-Development Agreement With Capsugel 30
Catalent Pharma Solutions Enters Into Agreement With Bend Research 31
CSIRO Enters Into Co-Development Agreement With Lonza 32
Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 33
Tillotts Pharma Enters into Licensing Agreement with BioWa and Lonza 34
CytoDyn Enters into Licensing Agreement with Lonza Sales 35
Xbiotech Enters into Licensing Agreement with Lonza Sales 36
Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 37
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 39
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 40
Pierre Fabre Enters into Licensing Agreement with Lonza 41
Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 42
Pierre Fabre Enters into Licensing Agreement with Lonza 43
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 44
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 45
Lonza Enters into Licensing Agreement with arGEN-X 47
Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 48
Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 49
Bend Research Enters Into Licensing Agreement With Affinium For SDD Technology 50
Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 51
Lonza Raise USD2.24 Billion in Rights Offering of Shares 52
Lonza Raises USD871 Million in Private Placement of Shares 53
Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 54
Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For US$316.5 Million 55
Lonza Completes Public Offering Of Bonds Due 2022 For US$112 Million 56
Lonza Completes Public Offering Of Bonds Due 2018 For US$213 Million 57
PolyPeptide to Acquire Peptides Business and Operations in Braine, Belgium from Lonza 58
Lonza Group Acquires micromacinazione from Cross 59
Lonza Acquires Capsugel from KKR & Co for USD5.5 Billion 60
Lonza Group Acquires PharmaCell 62
Lonza Acquires HansaBioMed Life Sciences 63
Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 64
Lonza Acquires Triangle Research Labs from PBM Capital 65
Lonza May Acquire Catalent 66
Capsugel Acquires Xcelience 67
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 68
PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 69
Capsugel Completes Acquisition Of Bend Research, Drug Delivery Technologies Company 70
Capsugel Belgium Acquires Encap Drug Delivery 71
Lonza Group Ltd, Key Competitors 72
Lonza Group Ltd, Key Employees 73
Lonza Group Ltd, Subsidiaries 74
Lonza Group Ltd, Joint Venture 77

List Of Figures

List of Figures
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Lonza Group Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Lonza Group Ltd (LONN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Lonza Group Ltd (Lonza) is a biopharmaceutical company that manufactures and develops chemical and biological active pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem

USD 250View Report

Lonza Group Ltd Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Lonza Group Ltd Company Profile is a detailed strategic and analytical report on Lonza Group Ltd. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

Uni-Bio Science Group Ltd (690) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Uni-Bio Science Group Ltd (Uni-Bio Science) is a pharmaceutical company that researches, commercializes, and develops novel biopharmaceutical products. The company offers development of drugs for the treatment of chronic conditions

USD 250View Report

Almac Group Ltd - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Almac Group Ltd (Almac) is a contract development and manufacturing organization provides integrated services to pharmaceutical and biotechnology companies. The company offers a comprehensive range of services across the lifecycle

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :99
Country :Switzerland
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube